Medical Doctor Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

David Jacobs

Pain Medicine Lutherville, MD Medical Doctor

NPI 1093178386 CMS profile 5698771

1312 Bellona Ave Ste 302, Lutherville, MD 21093

Open in the dashboard

General payments

$658

18 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, David Jacobs of Lutherville, MD is reported in the CMS Open Payments database as having received $658 across 18 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 33rd percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $105 3
2023 General $376 12
2022 General $110 1
2021 General $66 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Jacobs
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to David Jacobs were reported at $0. Among 1,144 Pain Medicine profiles paid that year, the median was $402 and the middle half received between $130 and $1,173.

Show as a table
Year David Jacobs Pain Medicine median Middle half National median
2019 $0 $409 $115–$1,311 $163
2020 $0 $214 $66–$666 $114
2021 $66 $299 $84–$899 $132
2022 $110 $335 $103–$1,149 $149
2023 $376 $376 $114–$1,228 $160
2024 $105 $387 $115–$1,173 $164
2025 $0 $402 $130–$1,173 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. Boston Scientific Corporation $447 12 payments
  2. Curonix LLC $71 1 payment
  3. SPR Therapeutics, Inc $57 2 payments
  4. Avanos Medical $51 1 payment
  5. Linvatec Corporation $17 1 payment
  6. Nevro Corp. $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Food and Beverage $658 18 payments
Products named General payments · program years 2021–2024
  1. AngioJet Ultra 5000A $123 3 payments
  2. Infinion 16 $110 1 payment
  3. PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A $71 1 payment
  4. SPRINT PNS System $57 2 payments
  5. COOLIEF* COOLED RADIOFREQUENCY $51 1 payment
  6. Peripheral RotaLink Plus $50 2 payments
  7. JETSTREAM SC $23 1 payment
  8. Innova Vascular $17 1 payment
  9. LINVATEC VIDEO ACCESSORIES $17 1 payment
  10. Omnia $15 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

1,191

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$13,777

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

2.8%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 432 $4,974
Pregabalin Generic 105 $2,160
Celecoxib Generic 110 $1,791
Duloxetine Hcl Generic 35 $866
Methocarbamol Generic 96 $765
Tramadol Hcl Generic 119 $640
Etodolac Generic 38 $613
Cyclobenzaprine Hcl Generic 31 $557
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 33 $429
Methylprednisolone Generic 67 $387

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$198,881

Of which drugs: $63

Medicare patients

750

Average age 76

Services billed

3,348

505 women, 245 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 34%
Ischemic heart disease 24%
Chronic kidney disease 23%
Depression 23%
Osteoporosis 21%
Cancer 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 125 566 $49

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

18 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record